Sakura Finetek USA launches new Genemed<sup>®</sup> branded, ready-to-use chromogenic in-situ hybridization (CISH) probes and reagents.

Sakura Finetek USA Press Release
August 1, 2023
Sakura Finetek USA launches new Genemed® branded, ready-to-use chromogenic in-situ hybridization (CISH) probes and reagents.
Contact: Erico von Bueren, Senior Director of Marketing and Strategy
TORRANCE, CA – Sakura Finetek USA, Inc. today announced the launch of new ready-to-use CISH probes and reagents for CISH testing.
“Sakura Finetek USA’s commitment to increasing our menu for IHC as well as ISH is vital to our mission of improving the clinical value and utility of Sakura Finetek branded products and advancing the quality of patient care.  Bringing CISH testing to our portfolio is critical to furthering the capabilities of our product line,” stated William Jennings, Senior Product Manager of Advanced Staining. These products are in vitro diagnostic devices (IVD) or analyte specific reagents (ASR).
The new products include:
  • Genemed® CISH Amplification Linker
  • Genemed® SSC Stringent Wash Buffer
  • Genemed® CISH probes (Kappa, Lambda, EBER, Positive Control, Negative Control)
About Genemed
Genemed IHC and ISH products offer you innovation that can only come from a company whose focus since 1987 has been geared toward producing clinically relevant antibodies for anatomic pathology. The Genemed antibody and probe portfolio offers a broad range of primary antibodies and probes suitable for immunohistochemistry (IHC) or in-situ hybridization (ISH) on formalin-fixed paraffin embedded (FFPE) tissue specimens. We primarily focus on in vitro diagnostics (IVD), which includes antibodies, detection systems, and ancillary reagents for clinical testing in histopathology laboratories.

About Sakura Finetek, USA, Inc.
With its U.S. office based in Torrance, California, Sakura Finetek is the global leader in advancing cancer diagnostics by providing integrated solutions for anatomic pathology and patient treatment through best-in-class innovation, quality, and customer care. With a strategic focus on end-to-end automation, Sakura Finetek continues to lead the industry in the development and commercialization of automated histopathology instrumentation and consumables for anatomic pathology.
Sakura Finetek systems dramatically increase efficiency, standardize results, and enable clinical laboratories to manage their daily workload more simply while significantly impacting patient care. Visit to learn more.
Erico von Bueren
Senior Director of Marketing and Strategy
Sakura Finetek USA, Inc.
1750 W. 214th St.
Torrance, CA 90501                                                                     MPRE0084 Rev A